Par Pharmaceutical starts shipping generic Sodium Edecrin following FDA approval

CHESTNUT RIDGE, N.Y. — Par Pharmaceutical announced Wednesday that the Food and Drug Administration had granted final approval of the company’s generic version of Sodium Edecrin (ethacrynate sodium) for injection.

 

The drug, which had annual sales of $40 million according to IMS Health, is meant to treat edema, and Par said it had begun shipping ethacrynate sodium in cartons containing one 50-mg single-dose vial.